Longeveron Announces 2026 Third Quarter Financial Results and Provides Business Update
Following reporting of results for the ELPIS II Phase 2b clinical trial, the Company has requested a
Following reporting of results for the ELPIS II Phase 2b clinical trial, the Company has requested a